Full-Time

Senior Clinical Research Associate

Posted on 8/19/2026

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Antibody discovery and licensing platform

No salary listed

Montreal, QC, Canada

In Person

Travel to clinical sites in Canada and the United States is required 60–70% of the time.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
FDA Regulations

Get referred to AbCellera Biologics

See people who can refer or advise you

Requirements
  • A degree in Life Sciences, Nursing, Pharmacy, or a related field.
  • At least 10 years of clinical research associate monitoring experience, with a proven track record managing complex clinical trials and multiple sites simultaneously.
  • Advanced, hands-on command of International Council for Harmonisation Good Clinical Practice, Food and Drug Administration, European Medicines Agency, and local regulatory requirements.
  • Strong stakeholder management skills and the ability to operate independently and make decisions with minimal oversight.
  • Strong problem-solving and risk-assessment abilities.
  • Willingness to travel to clinical sites in Canada and the United States 60–70% of the time.
  • French and English bilingual proficiency is required for Quebec sites.
Responsibilities
  • Own a portfolio of complex investigator sites and apply independent judgment to keep timelines and study objectives on track.
  • Execute monitoring activities from site selection and qualification through site initiation, routine monitoring, and close-out while ensuring regulatory compliance, data integrity, and operational excellence.
  • Conduct source data verification and documentation review across regulatory files and essential documents.
  • Translate enrollment, retention, and data-quality metrics into actionable insights and deliver timely monitoring-visit reports.
  • Own investigational product accountability across assigned sites.
  • Act as the primary point of contact between AbCellera and investigative sites and cultivate effective site relationships.
  • Lead the resolution of protocol deviations, including investigations into significant or complex compliance issues.
  • Anticipate and escalate study risks and drive quality standards and risk-based monitoring practices.
  • Serve as the subject-matter expert for assigned protocols and therapeutic areas and train site personnel.
  • Shape the development of other clinical research associates through hands-on mentorship, co-visits, and knowledge sharing.
  • Partner with data management, project management, and medical teams on enrollment strategy, site-management planning, and feasibility decisions.
  • Prepare investigative sites for sponsor, regulatory, and quality-assurance audits, identify gaps, strengthen inspection readiness, and support successful audit outcomes.
Desired Qualifications
  • Experience mentoring or training other clinical research associates.

AbCellera Biologics helps other companies and research teams find and develop antibody therapies. It uses a proprietary technology platform to identify antibody candidates and collaborates with pharmaceutical and biotech partners to accelerate drug discovery and development. The company's products are the antibody candidates and discovery services it provides under licensing or collaboration agreements, as well as its own internal therapeutic programs. Unlike many competitors, AbCellera emphasizes tackling difficult drug targets and building long-term partnerships with a wide range of clients, using data-driven, multidisciplinary approaches to speed up discovery. The goal is to deliver safe, effective antibody medicines to patients by advancing partner programs and its own pipeline through discovery, licensing, and development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2012

Get referred to AbCellera Biologics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 brought $200 million equity plus over $112 million partnership upfronts.
  • Positive ABCL635 Phase 2 data opens a large non-hormonal menopause market.
  • Vertex and Jazz collaborations expand AbCellera’s TCE platform into autoimmune disease and oncology.

What critics are saying

  • ABCL635 failure would crush AbCellera’s internal pipeline and August 2026 re-rating.
  • Q2 2026 revenue fell sharply; partner fees still dominate despite $675 million liquidity.
  • Jazz and Vertex both own downstream commercialization, limiting AbCellera’s long-term economics.

What makes AbCellera Biologics unique

  • AbCellera’s proprietary T-cell engager platform won Vertex and Jazz deals in July 2026.
  • ABCL635 showed positive Phase 2 menopause data on August 10, 2026, validating internal development.
  • The company combines discovery, engineering, and early manufacturing, unlike pure fee-for-service antibody shops.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
wallstreet:online AG
Aug 13th, 2026
AbCellera announces pricing of oversubscribed $200 million public offering of common shares and pre-funded warrants.

AbCellera announces pricing of oversubscribed $200 million public offering of common shares and pre-funded warrants. Foto: adobe.stock.com AbCellera Biologics Inc. (Nasdaq: ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant, which represents the per share public offering price of each common share less the $0.00001 per share exercise price for each pre-funded warrant. The gross proceeds to AbCellera from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares and pre-funded warrants are being sold by AbCellera. The offering is expected to close on August 14, 2026, subject to the satisfaction of customary conditions. AbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets are acting as joint book-running managers for the offering. The securities described above are being offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-285367) that was filed with the U.S. Securities and Exchange Commission (the "SEC") on February 27, 2025 and automatically became effective upon filing. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A final prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at [email protected]; UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, by email at [email protected]; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at [email protected] Diskutieren sie über die enthaltenen Werte. Business Wire (engl.) Autor folgen Verfasst von Letzte Änderung13.08.2026, 06:05 Im Artikel enthaltene Werte

Yahoo Finance
Aug 12th, 2026
AbCellera soars 60% as ABCL635 cuts menopause hot flashes in Phase 2 trial

AbCellera Biologics' shares surged 60.3% following positive Phase 2 trial results for ABCL635, its investigational antibody for menopause treatment. A single 600mg subcutaneous dose significantly reduced frequency and severity of moderate-to-severe hot flashes versus placebo over four weeks, whilst demonstrating favourable tolerability. The results position AbCellera as an emerging competitor in the large, underserved non-hormonal menopause therapy market. The company recently completed a $200 million equity offering to fund larger trials for ABCL635 and other programmes. However, investors face substantial risks. AbCellera continues posting widening net losses and remains dependent on future milestones and product revenue. The company's investment narrative projects $27.9 million revenue by 2029, requiring a 25% yearly revenue decline from current levels.

MarketScreener
Aug 11th, 2026
AbCellera launches $200M public offering to fund ABCL635 clinical programme

AbCellera Biologics has commenced an underwritten public offering of $200 million in common shares and pre-funded warrants. The clinical-stage biotechnology company will use the net proceeds to fund continued research, development and clinical advancement of its internal pipeline, including its lead clinical programme, ABCL635, as well as for working capital and general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets are acting as joint book-running managers for the proposed offering. The offering is subject to market and other conditions, with no assurance as to whether or when it may be completed. AbCellera focuses on discovering and developing antibody-based medicines in endocrinology, women's health, immunology and oncology.

Yahoo Finance
Aug 6th, 2026
AbCellera secures $110M in partnerships, advances hot flash treatment ahead of schedule

AbCellera Biologics reported a net loss of roughly $55 million for Q2 2026, up from $35 million in the same quarter of 2025. Total revenue dropped to approximately $4 million from $17 million year-over-year. The company completed enrollment for its phase 2 study of ABCL-635 for treating hot flashes ahead of schedule, with top-line data expected soon. Phase 1 data showed robust target engagement with a clean safety profile, including no increase in liver enzymes. AbCellera secured over $110 million in upfront cash from new T-cell engager collaborations with Vertex and Jazz Pharmaceuticals. The company maintains over $565 million in cash and equivalents, plus roughly $110 million in committed government funding, providing at least three years of runway. Research and development expenses increased by approximately $7 million year-over-year. The company missed its internal goal of advancing another programme into IND-enabling activities in the first half of 2026. AbCellera added two experienced independent directors to its board, bringing expertise in oncology, women's health, immunology, and endocrinology.

The Montreal Gazette
Jul 29th, 2026
AbCellera announces collaboration with Vertex to discover multispecific t-cell engagers for autoimmune diseases and other conditions.

AbCellera announces collaboration with Vertex to discover multispecific t-cell engagers for autoimmune diseases and other conditions. VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. "We are excited to collaborate with Vertex, a recognized leader in innovation, to accelerate the development of new, transformative therapies," said Carl...